OLD National Bancorp IN Takes Position in Endologix Inc. (ELGX)
OLD National Bancorp IN acquired a new position in shares of Endologix Inc. (NASDAQ:ELGX) during the second quarter, Holdings Channel reports. The firm acquired 10,365 shares of the company’s stock, valued at approximately $129,000.
Other institutional investors have also recently bought and sold shares of the company. Legal & General Group Plc increased its stake in Endologix by 34.9% in the first quarter. Legal & General Group Plc now owns 12,570 shares of the company’s stock worth $106,000 after buying an additional 3,252 shares during the period. Villere ST Denis J & Co. LLC acquired a new stake in Endologix during the second quarter worth approximately $134,000. Quantitative Systematic Strategies LLC acquired a new stake in Endologix during the second quarter worth approximately $215,000. Fox Run Management L.L.C. acquired a new stake in Endologix during the second quarter worth approximately $249,000. Finally, Rothschild Asset Management Inc. acquired a new stake in Endologix during the second quarter worth approximately $364,000.
Shares of Endologix Inc. (NASDAQ:ELGX) traded up 0.55% on Tuesday, reaching $12.86. 569,607 shares of the company traded hands. The company’s market capitalization is $1.06 billion. The firm has a 50-day moving average of $12.22 and a 200-day moving average of $11.61. Endologix Inc. has a 52-week low of $6.51 and a 52-week high of $14.50.
Endologix (NASDAQ:ELGX) last released its quarterly earnings results on Tuesday, August 2nd. The company reported ($0.13) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.20) by $0.07. Endologix had a negative return on equity of 41.88% and a negative net margin of 82.39%. The company earned $51 million during the quarter, compared to analysts’ expectations of $46.30 million. During the same quarter in the prior year, the business posted ($0.18) earnings per share. The company’s revenue for the quarter was up 29.1% compared to the same quarter last year. On average, equities research analysts forecast that Endologix Inc. will post ($0.74) earnings per share for the current fiscal year.
A number of equities research analysts have commented on the company. Leerink Swann set a $13.00 target price on Endologix and gave the company a “hold” rating in a report on Saturday. BMO Capital Markets reissued a “buy” rating and issued a $15.00 target price on shares of Endologix in a report on Wednesday, August 3rd. BTIG Research reissued a “buy” rating and issued a $16.00 target price on shares of Endologix in a report on Wednesday, August 3rd. Piper Jaffray Cos. reissued an “overweight” rating and issued a $15.00 target price on shares of Endologix in a report on Wednesday, August 3rd. Finally, Oppenheimer Holdings Inc. set a $15.00 target price on Endologix and gave the company a “buy” rating in a report on Wednesday, August 3rd. One research analyst has rated the stock with a sell rating, three have issued a hold rating and nine have given a buy rating to the stock. The stock has an average rating of “Buy” and an average target price of $13.79.
In other news, insider Michael V. Chobotov sold 14,000 shares of the stock in a transaction on Friday, August 5th. The stock was sold at an average price of $12.40, for a total value of $173,600.00. Following the completion of the transaction, the insider now owns 189,269 shares of the company’s stock, valued at $2,346,935.60. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, VP Jose A. Lima sold 4,710 shares of the stock in a transaction on Friday, August 19th. The stock was sold at an average price of $11.68, for a total value of $55,012.80. Following the completion of the transaction, the vice president now directly owns 42,594 shares of the company’s stock, valued at approximately $497,497.92. The disclosure for this sale can be found here. 3.90% of the stock is owned by insiders.
Endologix Company Profile
Endologix, Inc is engaged in developing, manufacturing, marketing and selling medical devices for the treatment of aortic disorders. The Company’s products are intended for the treatment of abdominal aortic aneurysms (AAA). The AAA products are built on one of two platforms, including traditional minimally invasive endovascular repair (EVAR) or endovascular sealing (EVAS), its solution for sealing the aneurysm sac while maintaining blood flow through two blood flow lumens.
Want to see what other hedge funds are holding ELGX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Endologix Inc. (NASDAQ:ELGX).
Receive News & Ratings for Endologix Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endologix Inc. and related companies with MarketBeat.com's FREE daily email newsletter.